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Expression Analysis of the Hippo
Cascade Indicates a Role in Pituitary
Stem Cell Development
Emily J. Lodge, John P. Russell, Amanda L. Patist, Philippa Francis-West and
Cynthia L. Andoniadou*
Craniofacial Development and Stem Cell Biology, Dental Institute, King’s College London, London, UK
The pituitary gland is a primary endocrine organ that controls major physiological
processes. Abnormal development or homeostatic disruptions can lead to human
disorders such as hypopituitarism or tumors. Multiple signaling pathways, includingWNT,
BMP, FGF, and SHH regulate pituitary development but the role of the Hippo-YAP1/TAZ
cascade is currently unknown. In multiple tissues, the Hippo kinase cascade underlies
neoplasias; it influences organ size through the regulation of proliferation and apoptosis,
and has roles in determining stem cell potential. We have used a sensitive mRNA
in situ hybridization method (RNAscope) to determine the expression patterns of the
Hippo pathway components during mouse pituitary development. We have also carried
out immunolocalisation studies to determine when YAP1 and TAZ, the transcriptional
effectors of the Hippo pathway, are active. We find that YAP1/TAZ are active in
the stem/progenitor cell population throughout development and at postnatal stages,
consistent with their role in promoting the stem cell state. Our results demonstrate for
the first time the collective expression of major components of the Hippo pathway during
normal embryonic and postnatal development of the pituitary gland.
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INTRODUCTION
The pituitary gland is a critical endocrine organ that controls multiple essential physiological
processes such as metabolism, stress response, growth and reproduction. It is not surprising
therefore, that abnormal pituitary function leads to human disease, including hypopituitarism and
pituitary tumors, which can be associated with high morbidity and mortality. Hypopituitarism
has an estimated prevalence of 45.5 per 100,000 (Schneider et al., 2007) and clinically relevant
pituitary adenomas are reported to have a mean prevalence of 94 per 100,000 although up to one
in six individuals are found to carry pituitary microadenomas (Ezzat et al., 2004; Daly et al., 2006).
Understanding the genes and pathways that control normal pituitary development and function,
and their likely involvement in disease, is required to speed up the discovery of new tools to improve
patient management.
The pituitary develops from two discrete embryonic tissues; oral ectoderm, which gives rise
to the endocrine anterior pituitary comprised of the intermediate and anterior lobes, and neural
ectoderm (ventral diencephalon), which gives rise to the posterior pituitary, which is connected
with the hypothalamus. Inmice, the hypophyseal placode, the primordium of the anterior pituitary,
is first identifiable as a thickening in the oral ectoderm at 8.0 days post coitum (dpc). From
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9.0dpc the placode invaginates, forming the anterior pituitary
primordium termed Rathke’s pouch (RP). The overlying
ventral diencephalon then evaginates toward and contacts
RP by 10.5dpc to form the infundibulum (de Moraes et al.,
2012; Rizzoti, 2015). Subsequently, RP detaches from the oral
epithelium, to form the definitive pouch by 12.5dpc. The
definitive pouch retains a central lumen that is lined by SOX2+
uncommitted progenitor cells (de Moraes et al., 2012; Rizzoti,
2015). Descendants of these SOX2+ cells restrict their fate to
three lineages (Fauquier et al., 2008; Andoniadou et al., 2013;
Rizzoti et al., 2013), which are characterized by expression of
transcription factors PIT1, TPIT, and SF1. PIT1+ progenitor
cells differentiate into prolactin-secreting lactotrophs, growth
hormone-secreting somatotrophs and thyroid-stimulating
hormone-secreting thyrotrophs; TPIT+ progenitors give rise to
adrenocorticotrophic hormone-secreting corticotrophs in the AP
and melanocyte-stimulating hormone-secreting melanotrophs
in the IL. Lastly, SF1+ progenitors produce luteinizing hormone-
and follicle-stimulating hormone-secreting gonadotrophs.
A proportion of SOX2+ cells (3–5% of total pituitary cells)
persist into adult life (Fauquier et al., 2008; Jayakody et al.,
2012; Andoniadou et al., 2013). Postnatally, these SOX2+ cells
are predominantly found in a thin epithelial layer between
the anterior and intermediate lobes of the pituitary (marginal
zone), and groups of SOX2+ cells are also dispersed within the
parenchyma.
Multiple signals are required for correct pituitary
development, however the activity or role of the Hippo pathway
has not been previously studied. The infundibulum expresses
FGF8, FGF10, and BMP2 from 9.0dpc (Treier et al., 1998, 2001),
which diffuse to form a dorsal-ventral gradient. Changes in the
extent of these expression domains within the infundibulum
directly influence anterior pituitary size. In the absence of FGF
signaling, RP is initially specified but cells fail to proliferate
and undergo apoptosis (De Moerlooze et al., 2000; Ohuchi
et al., 2000). FGF activity is mediated through the transcription
factor LIM Homeobox 3 (LHX3) (Ericson et al., 1998), required
for progenitor specification and proliferation (Sheng et al.,
1997). SHH is expressed in the non-hypophyseal oral ectoderm
and ventral diencephalon surrounding the infundibulum and
signals to the developing RP (Treier et al., 2001; Khonsari et al.,
2013). Loss of SHH signaling leads to a reduction in pituitary
tissue, a phenotype attributed both to defective patterning and
proliferation. The mesenchyme around the developing pituitary,
derived from the neural crest rostrally and from the paraxial
mesoderm caudally (Jiang et al., 2002; McBratney-Owen et al.,
2008), expresses WNT and BMP signals that also influence
morphogenesis, proliferation and cell-fate specification (Treier
et al., 1998; Davis and Camper, 2007). WNT ligands have a role
in promoting pituitary progenitor proliferation and PIT1-lineage
specification as well as for correct expression of FGF and BMP
factors (Cha et al., 2004; Potok et al., 2008; Gaston-Massuet et al.,
2011; Andoniadou et al., 2013). Similarly, BMP2 and BMP4 are
required for pituitary growth and lineage specification (Takuma
et al., 1998; Treier et al., 1998).
The Hippo pathway regulates organ size through the control
of stem cell activity, proliferation and apoptosis. The pathway
is an inhibitory phosphorylation cascade first identified in
Drosophila, where mutations in the Hippo (Hpo) kinase led to
over-proliferation in imaginal discs and tissue overgrowth in
the adult fly (Wu et al., 2003). The mammalian core Hippo
pathway consists of MST1/MST2 kinases (Hpo homologs, a.k.a.
STK4/STK3), which activate LATS1/LATS2 kinases, leading to
phosphorylation of effectors YAP1 and TAZ (WWTR1) at
multiple sites. These are then retained in the cytoplasm via 14-
3-3 (Hao et al., 2008) or ubiquitinated and degraded (Zhao et al.,
2011). When the Hippo pathway is not active, YAP1 and TAZ can
enter the nucleus and bind to transcription factors TEAD1-4 (Ota
and Sasaki, 2008; Zhao et al., 2008), to activate transcription of
stemness, proliferation and anti-apoptotic genes. Loss of function
of core kinases leads to increased proliferation in several tissues,
most obviously in the liver (Lu et al., 2010), heart (Heallen et al.,
2011, 2013), and intestine (Cai et al., 2010; Imajo et al., 2015).
YAP1/TAZ regulate proliferation, survival and differentiation
and are active inmany stem cell populations including embryonic
stem cells (Lian et al., 2010). Many factors have been implicated
in the regulation of YAP1/TAZ via modulation of the core
Hippo pathway. These include the proto-cadherins FAT4 and
DCHS1 (Cappello et al., 2013; Bagherie-Lachidan et al., 2015)
where loss of FAT4/DCHS1 has been reported to result in
an increase in YAP1 and TAZ activity in neuronal cells and
nephron progenitors. SOX2 has been shown to antagonize
the Hippo pathway, leading to the nuclear accumulation
of YAP1 and TAZ (Basu-Roy et al., 2015). Additionally,
SOX2 has been shown to induce transcription of Yap1 in
mesenchymal stem cells and osteoprogenitors (Seo et al., 2013),
whilst in developing lungs, YAP1 can induce Sox2 expression
(Mahoney et al., 2014). Therefore YAP1/TAZ is strongly
associated with the stem cell state. In this manuscript we have
analyzed in detail the expression of components of the Hippo
pathway in the developing pituitary gland and demonstrate
its activity in SOX2+ cells during embryonic and postnatal
development.
MATERIALS AND METHODS
Animals and Tissue Processing
Procedures were carried out in accordance with the UK Animals
(Scientific Procedures) Act 1986, subject to KCL local Ethical
Review. Wild type CD1 females were mated with wild type
CD1 males for the generation of embryos. Sox2-Egfp animals
have been previously described (Ellis et al., 2004). These were
maintained as heterozygotes on a CD1 background. Midday of
the day of vaginal plug was considered as 0.5 days post coitum
(dpc). Dissected embryos and postnatal tissues were fixed in 10%
neutral buffered formalin (NBF) at room temperature for 36 h,
then dehydrated through a graded ethanol series and processed
for paraffin embedding as previously described (Gaston-Massuet
et al., 2008; Sajedi et al., 2008). Samples were sectioned along
the sagittal plane for embryos between 9.5dpc and 13.5dpc and
frontal plane for older embryos and postnatal pituitaries, at
a thickness of 7 µm for immunofluoresence and 4 µm for
RNAscope mRNA in situ hybridization.
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Immunofluorescence
Samples were dewaxed in histoclear twice for 10 min, followed by
rehydration through a descending ethanol series then washed in
water. Antigen retrieval was carried out in citrate-based Declere
Unmasking Solution (Cell Marque) in a steamer twice for 30min,
followed by washing in PBT. For tyramide specific amplification
[TSA, for antibodies against YAP1 (Cell Signaling 4912, 1:1000),
pYAP (S127) (Cell Signaling 4911S, 1:1000) and TAZ (Sigma
HPA007415, 1:1000)], slides were washed in TNT buffer (0.1M
Tris-HCl, pH7.5, 0.15M NaCl, 0.05% Tween-20). Slides were
blocked for 1 h in TNB [0.1M Tris-HCl pH7.5, 0.15MNaCl, 0.5%
Blocking Reagent (FP1020, Perkin Elmer)], and incubated with
primary antibody overnight at 4◦C in TNB. Following washes,
species-specific biotinylated antibody was applied for 1 h at
room temperature in TNB. Following washes in TNT, slides were
incubated in ABC solution (Vector Laboratories, pk-6100) for 30
min in the dark then for 10 min at room temperature in TSA-Cy3
diluted in Stock Solution (Perkin Elmer, NEL760001). Slides were
washed andmounted with soft-set mounting mediumwith DAPI
(Vector Laboratories, Z1007) ready for imaging. For double
immunofluorescence with GFP, the above conditions were used,
with the inclusion of chicken anti-GFP primary antibody (Abcam
ab13970, 1:350) and secondary goat anti-chicken Alexa Fluor
488 (Invitrogen A11039, 1:500). For antibodies against SOX2
(Abcam ab97959, 1:300) and Endomucin (Abcam ab106100,
1:500), blocking was carried out in Blocking Buffer (0.15%
glycine, 2 mg/ml BSA, 0.1% Triton-X in PBS) with 10% sheep
serum for minimum 1 h at room temperature. Primary antibody
solution was applied overnight at 4◦C, diluted in Blocking Buffer
with 1% sheep serum. Slides were washed and then incubated
in goat anti-rabbit biotinylated (Abcam ab6720, for α-SOX2) or
goat anti-rat Alexa Fluor 633 (Life Technologies A-21094, for
α-Endomucin) for 1 h at room temperature, diluted to 1:350
in Blocking Buffer with 1% sheep serum. After washing, slides
were incubated in Streptavidin-488 (Life Technologies S11223)
at 1:500 dilution in Blocking Buffer with 1% sheep serum for 1 h
a room temperature. Slides were washed and mounted as above.
mRNA In situ hybridization
Tissue sections cut at 4 µm thickness were processed for mRNA
in situ detection using the RNAscope 2.0 Fast Red Detection
Kit (Advanced Cell Diagnostics), according to manufacturer’s
recommendations. For 10.5dpc and 12.5dpc embryos, pre-
treatment was carried out at the recommended “mild” timings
and for older embryos or postnatal tissues, “standard” timings
were used. RNAscope probes used: Hesx1, Sox2, Mst1 (Stk4),
Mst2 (Stk3), Lats1, Lats2, Yap1, Tead1, Tead2, Tead3, Tead4,
Fat3, Fat4, andDchs1 (Advanced Cell Diagnostics). To control for
background, we used a negative control probe against the Bacillus
subtilis dihydrodipicolinate reductase, dapB (Advanced Cell
Diagnostics) (Figure S1). Sections were weakly counterstained
with hematoxylin.
Microscopy
For fluorescent images, slides were visualized on a TCS
SP5 confocal system (Leica Microsystems (UK) Ltd). Images
were captured using a HCX Plan-Apochromat CS 20x/0.7
dry objective and HCX Plan-Apochromat CS 63x/1.3 Glycine
objective (both Leica Microsystems (UK) Ltd). The DAPI,
AlexaFluor 488, 594, and 633 conjugate dyes were excited with
405, 488, 561, and 633 nm lasers respectively. Z-stack images were
acquired at a total thickness of 3 µm. Images were processed
for maximum intensity z-projections using Fiji (Schindelin
et al., 2012). For brightfield images, slides were scanned using
a NanoZoomer-XR Digital slide scanner (Hamamatsu). Panels
were compiled using Adobe Photoshop to create the figures.
RESULTS
To determine reliability of the RNAscope in situ hybridization in
the pituitary we first validated this method by analysis of Hesx1,
which has a known pattern, only expressed during development.
It is expressed strongly in oral ectoderm subsequently fated
to become Rathke’s pouch at 8.5dpc (Cajal et al., 2012), and
persists in RP epithelium until 11.5dpc with levels of expression
decreasing thereafter (Thomas and Beddington, 1996). Using
the RNAscope in situ hybridization method for sensitive mRNA
detection, we confirmed strong expression of Hesx1 in RP
at 10.5dpc (Figure 1A, arrowhead), which extended rostrally
in the oral epithelium. No expression was detected in the
pharyngeal endoderm as previously reported (posterior limit of
expression noted by arrow). Expression of Hesx1 was barely
detectable at 12.5dpc and 13.5dpc (Figures 1B,C) with presence
of only sporadic transcripts (Figure 1C′ magnified boxed region
in C). Additionally, we investigated expression of Sox2, which
marks progenitors/stem cells in the pituitary, using this method.
Robust expression of Sox2 transcripts was detected in RP and
the developing ventral diencephalon, with complete absence
of expression in mesenchyme surrounding the pouch at all
stages (Figure 1). Expression of Sox2 is known to be down-
regulated in committed lineages of the pituitary gland, which
we confirmed at 13.5dpc; there is an absence of transcripts
in the ventral anterior pituitary where cells are undergoing
commitment (Figure 1F, asterisk). Expression persisted dorsally,
specifically in the marginal epithelium surrounding the pouch
where the uncommitted cells reside (arrowheads in Figure 1F).
Expression of Upstream Hippo Regulators
We next sought to characterize the expression of proposed
upstream regulators of the Hippo cascade, homologs of
Drosophila Ds and Ft, whose protein products act as ligand-
receptor pair. We analyzed expression of Dchs1 and Fat4 that
have closest homology to Ft and Ds, as well as Fat3, which is
detectable in developing pituitary tissue (Karine Rizzoti, personal
communication). Previous studies have reported absence of
expression of the remaining homologs Fat1, Fat2, and Dchs2
in the pituitary gland (Diez-Roux et al., 2011). At 10.5dpc
we did not observe Dchs1 expression in RP epithelium but
transcripts were detected in the caudal mesenchyme as well as
in the ventral diencephalon (Figure 2A). Expression in RP was
observed at 12.5dpc at low levels and persisted until at least
17.5dpc where it was detected both in the anterior and posterior
pituitary and in the hypothalamus, with lowest expression in
cells lining the third ventricle (Figures 2B–E). At 10.5dpc we
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FIGURE 1 | Validation of RNAscope method in the pituitary gland. RNAscope mRNA in situ hybridization using probes against Hesx1 and Sox2 on wild type
CD1 embryos at stages between 10.5dpc and 13.5dpc. (A–C) At 10.5dpc Hesx1 is expressed in the oral epithelium and Rathke’s pouch (arrowhead), but excluded
from the pharyngeal endoderm. The posterior limit of expression is indicated by the arrow in (A). At 12.5dpc and 13.5dpc expression is reduced although still
detectable (C′, boxed area in C). (D–F) Sox2 is expressed in Rathke’s pouch at 10.5dpc (arrowheads) as well as neural tissue, oral epithelium and pharyngeal
endoderm. Expression decreases in the ventral pouch where committed cells arise (asterisk in F) and persists periluminal and in the dorsal RP (arrowheads in E,F). For
clarity, the developing anterior pituitary primordium is indicated by the dotted outline in (E,F). Abbreviations: rp, Rathke’s pouch; vd, ventral diencephalon; m,
mesenchyme; or, oral ectoderm; pe, pharyngeal endoderm; inf, infundibulum; sph, sphenoid. Sagittal sections, axes in (A) applicable to all panels: d, dorsal; v, ventral;
r, rostral; c, caudal. Scale bars 200 µm.
observed robust expression of Fat3 in the developing pouch,
in ventral diencephalon and caudal mesenchyme (Figure 2F).
Expression in RP persisted at lower levels until at least 17.5dpc
(Figures 2G–J, arrowheads in Figures 2G,H), where strongest
expression was detected in cells lining the third ventricle
(arrowheads in Figures 2I,J) as well as in posterior pituitary
tissue (arrow in Figure 2J). Fat4 transcripts were present from
10.5dpc throughout RP (arrowheads in Figure 2K) and oral
epithelium but excluded from the pharyngeal endoderm (arrow).
Strong expression was detected in surrounding mesenchyme.
At 12.5dpc very strong expression was detected at the rostral
tip (arrowheads in Figure 2L) with low levels of transcripts in
RP epithelium. There was also expression in the infundibulum
(arrow in Figures 2L,M) and surroundingmesenchyme. Fat4was
still expressed at 17.5dpc in sporadic cells of the anterior and
posterior pituitary (arrows in Figures 2N,O) and surrounding
mesenchyme (arrowheads in Figure 2N).
Expression of Pathway Kinases
In multiple tissues, MST1 and MST2 have redundant functions.
At all stages analyzed, expression of both Mst1 and Mst2
was observed throughout the developing pituitary between
10.5dpc and 17.5dpc (Figures 3A–J). We detected salt and
pepper expression in Rathke’s pouch, the infundibulum and
their subsequent derivatives. Both genes were also expressed in
neural structures from 10.5dpc with few sporadic cells displaying
transcripts in surrounding mesenchyme at 10.5dpc and 12.5dpc.
We observed strong Lats1 expression at all stages throughout
the oral epithelial-derived and neural tissues (Figures 3K–O).
From 13.5dpc we observed a ventral bias in the developing
pituitary, with the dorsal epithelium surrounding the
lumen (future intermediate lobe) displaying lower expression
(arrowhead in Figure 3M). As seen for Mst1/Mst2, expression
in the mesenchyme was only detected in occasional single
cells at 10.5dpc but was abundant from 12.5dpc. Expression of
Lats2 was very low at all stages analyzed, across the developing
pituitary and surrounding tissues (Figures 3P–T), but detectable
(Figure 3T′, magnified boxed area in Figure 3T).
Expression of Hippo Pathway Effectors
When YAP1 and TAZ are not phosphorylated by LATS kinases
they can associate with TEAD transcription factors in the
nucleus to promote expression of target genes. We sought to
determine the expression patterns of Yap1 and Tead1-Tead4
in the developing pituitary. We were not able to determine
the expression of Taz mRNA using this method. Yap1 showed
robust expression in Rathke’s pouch and surrounding tissues at
10.5dpc (Figure 4A). By 12.5dpc there was strong expression
in the dorsal aspect of the pouch in the epithelium (Figure 4B
arrowhead), reduced expression in the expanding ventral portion
and no expression in the rostral tip (arrow). This pattern
was maintained at 13.5dpc and new tissue in the ventral
region that is undergoing commitment showed low expression
(arrowhead in Figure 4C). At 15.5 and 17.5dpc, Yap1 transcripts
remained strong in the intermediate lobe, marginal zone of
the anterior lobe and in scattered groups of cells throughout
the anterior lobe (Figures 4D,E, black arrowheads). Yap1 was
expressed in neural tissue and surrounding mesenchyme at all
stages, maintained until 17.5dpc when it was expressed in the
posterior lobe, the cell layer surrounding the third ventricle
(white arrowheads in Figures 4D,E) and in mesenchyme-derived
connective tissue surrounding the gland. From the four Tead
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FIGURE 2 | Expression of putative upstream Hippo pathway regulators during pituitary development. RNAscope mRNA in situ hybridization using probes
against Dchs1, Fat3 and Fat4 on sections of wild type CD1 embryos between 10.5dpc and 17.5dpc. (A–E) Dchs1 is expressed in mesenchyme surrounding Rathke’s
pouch and in neural tissue but absent from Rathke’s pouch epithelium (A). Expression in mesenchyme and neural tissue persists at 12.5dpc (B) and 13.5dpc (C)
where transcripts are also detectable in RP (arrowhead in B). Expression in all pituitary lobes, the hypothalamus and surrounding mesenchyme is detectable at
15.5dpc (D) and 17.5dpc (E). Note the reduced expression of Dchs1 in the epithelium surrounding the third ventricle in (D,E). (F–J) Fat3 is strongly expressed in
Rathke’s pouch (arrowheads), surrounding mesenchyme, and neural tissue at 10.5dpc (F). Reduced levels are detected in all tissues between 12.5dpc and 17.5dpc.
At 12.5dpc there is a dorsal bias in expression in RP (G), more clearly visible at 13.5dpc (arrowheads in H). Strong expression is detected in the epithelium
surrounding the third ventricle at 15.5dpc and 17.5dpc (arrowheads in I,J) and in the posterior pituitary (arrow in J). (K–O) Fat4 transcripts are detected in RP at
10.5dpc (arrowheads in K), in surrounding mesenchyme and neural tissue but excluded from the pharyngeal endoderm (arrow in K). Note the very strong expression
in the rostral tip of the anterior pituitary (arrowheads in L,M) at 12.5pc and 13.5dpc and in the ventral diencephalon and infundibulum (arrows in L,M), persisting in the
posterior lobe (arrows in N,O). Expression is high in surrounding mesenchyme (arrowheads in N). The box in (N) shows the epithelium around the third ventricle
displaying low-level expression. The outlines in (D,E,I,J,N,O) surround anterior pituitary tissue derived from Rathke’s pouch. Abbreviations: rp, Rathke’s pouch; vd,
ventral diencephalon; m, mesenchyme; oe, oral ectoderm; pe, pharyngeal endoderm; inf, infundibulum; sph, sphenoid; rt, rostral tip; pl, posterior lobe; al, anterior
lobe; il, intermediate lobe; hy, hypothalamus; 3v, third ventricle. Sagittal sections between 10.5dpc and 13.5dpc and frontal between 15.5dpc and 17.5dpc. Axes in
(A) applicable to (A–C,F–H,K–M: d, dorsal; v, ventral; r, rostral; c, caudal). Axes in (D) applicable to (D–E,I–J,N–O: d, dorsal; v, ventral; ri, right; le, left). Scale bars
200 µm.
genes, Tead2 expression was the strongest (Figures 4K–O).
This was reminiscent of the expression pattern of Yap1:
strong expression in RP and all surrounding tissues at 10.5dpc
(Figure 4K), strong expression in RP epithelium at 12.5dpc and
13.5dpc (Figures 4L,M, arrowheads) but no expression in the
rostral tip (Figures 4L,M, arrows) and reduced expression in the
ventral pituitary primordium at 13.5dpc (Figure 4M, asterisk).
Tead2 expression remained very high at 15.5dpc in the marginal
zone (Figure 4N, black arrowhead) and intermediate lobe and
in scattered groups of cells throughout the anterior lobe. Levels
of expression were reduced but present at 17.5dpc (Figure 4O,
black arrowhead). The posterior lobe also expressed high levels of
Tead2, as did cells surrounding the third ventricle (Figures 4N,O,
white arrowheads). Tead1 and Tead3were expressed at low levels
at all stages examined (Figures 4F-J, P-T) and Tead4 was not
expressed (Figures 4V-Y) except for low levels of transcript in RP
at 10.5dpc only (Figures 4U,U′ arrowheads).
Localization of YAP1 and TAZ Proteins
In order to infer activity of the Hippo kinase cascade, we
investigated the localization of effector proteins TAZ, total
YAP1, as well as the inactive phosphorylated form of YAP1
(S127). TAZ and YAP1 had similar localization at 10.5dpc; they
appeared nucleo-cytoplasmic with a bias for the apical cytoplasm
of RP epithelium (Figures 5A,F, arrowheads). Inactive YAP1,
marked by pYAP1 was strongly cytoplasmic and also displayed
an apical bias (Figure 5K, arrowheads). All three antibodies
marked cells in the mesenchyme and neural tissue. At 12.5dpc
and 13.5dpc YAP1 and TAZ both localized mostly in nuclei of
cells in RP epithelium, with stronger expression in the dorsal
RP epithelium at 12.5dpc, which persisted at 13.5dpc for YAP1
(yellow arrowheads in Figures 5B,G,H). In the ventral portion
of the epithelium there was nuclear localization in a thin cell
layer surrounding the cleft. Little expression was observed in
more ventral regions (asterisk in Figures 5B,C,G,H), and no
expression in the rostral tip (arrowheads in Figures 5B,C,G,H).
Phosphorylated YAP1 was cytoplasmic in cells both in the
dorsal and ventral regions at both stages but completely absent
from the rostral tip (arrowheads in Figures 5L,M). Expression
was stronger in the ventral epithelium than the dorsal (yellow
arrowheads in Figures 5L,M), the reverse of the observed pattern
for total YAP1 and TAZ. At 15.5dpc and 17.5dpc YAP1 and
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FIGURE 3 | Expression of Hippo kinase genes during embryonic development of the pituitary gland. RNAscope mRNA in situ hybridization using probes
against Mst1, Mst2, Lats1, and Lats2 on sections of wild type CD1 embryos between 10.5dpc and 17.5dpc. (A–J) Transcripts of Mst1 (A–E) and Mst2 (F–J) are
detectable in all tissues at low levels, at all stages analyzed. Yellow boxes in (D,I) are of the epithelium around the third ventricle. Magnifications of boxed regions in
(E,J) at 17.5dpc show positive staining in the anterior pituitary (E′,J′). (K–O) Lats1 transcripts are detectable in RP and neural tissue at 10.5dpc (K) and persist until
17.5dpc (L–O and O′ magnification of boxed region in O). Note the ventral bias in expression in RP at 13.5dpc (arrowhead in M). Lower levels of expression are
detected in surrounding mesenchyme. (P–T) Very low levels of Lats2 transcripts are detected in all tissues at all stages analyzed (note positive expression in T’,
magnification of boxed region in T at 17.5dpc). Abbreviations: rp, Rathke’s pouch; vd, ventral diencephalon; m, mesenchyme; inf, infundibulum; sph, sphenoid; rt,
rostral tip; pl, posterior lobe; al, anterior lobe; il, intermediate lobe; hy, hypothalamus; 3v, third ventricle. Sagittal sections between 10.5dpc-13.5dpc and frontal
between 15.5dpc and 17.5dpc. Axes in (A) applicable to (A–C,F–H,K–M,P–R: d, dorsal; v, ventral; r, rostral; c, caudal). Axes in (D) applicable to (D,E,I,J,N,O,S,T: d,
dorsal; v, ventral; ri, right; le, left). Scale bars 200 µm.
TAZ were nucleo-cytoplasmic in the marginal zone epithelium
surrounding the cleft on both sides, in the intermediate and
anterior lobes (arrowheads in Figures 5D,E,I,J). TAZ protein
was detected in a broader domain surrounding the epithelium
than YAP1 (Figure 5E). They were both present in cells scattered
around the anterior pituitary and in structures resembling blood
vessels (arrows in Figures 5D,E,J). Inactive phosho-YAP1 was
present in the cytoplasm of cells in the marginal zone epithelium
(arrowheads in Figures 5N,O) and in many cells throughout the
anterior and intermediate lobes at both stages. The posterior lobe
stained with all three antibodies, nucleo-cytoplasmic for TAZ and
cytoplasmic for YAP1 and phospho-YAP1.
We next investigated the localization of TAZ, YAP1, and
phospho-YAP1 in sections of postnatal pituitary glands at P21,
a time following the peak postnatal proliferative stage, when
the gland is still expanding and undergoing major hormonal
profile changes at weaning. We found that YAP1 and TAZ
were primarily nuclear in epithelial cells lining the pituitary
cleft (Figures 6B,C), which express the stem cell marker SOX2
(Figure 6A, arrowheads). Nucleo-cytoplasmic staining was also
seen in cells associated with blood vessels (arrows in inserts
in Figures 6B,C). The pattern of blood vessels was revealed
by staining using antibodies against endomucin (Figure 6A,
arrows). Nucleo-cytoplasmic staining for YAP1 and TAZ was
also seen in scattered cells throughout the anterior lobe, where
higher proportions were positive for TAZ (yellow arrowheads in
Figure 6B, inserts). Inactive phosphorylated YAP1 was localized
in the cytoplasm of cells in the marginal zone epithelium,
stronger in some regions (arrowheads in Figure 6D indicating
stronger staining). There was diffuse expression in the anterior
pituitary and cytoplasmic staining in cells lining blood vessels
(arrows in Figure 6D). In order to determine localization of
TAZ, YAP1 and pYAP1 specifically in SOX2+ cells we carried
out double immunofluorescence staining on sections at P21 from
Sox2Egfp/+ animals, using antibodies against GFP tomark SOX2+
cells (Figures 6E–G). We find nuclear localisation of both TAZ
and YAP1 in cells positive for GFP (arrows in Figures 6E,F).
Levels of pYAP1 in the epithelium do not correlate with GFP
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FIGURE 4 | Expression of the Hippo pathway effectors during embryonic development of the pituitary gland. RNAscope mRNA in situ hybridization using
probes against Yap1, Tead1, Tead2, Tead3, and Tead4 on sections of wild type CD1 embryos between 10.5dpc and 17.5dpc. (A–E) Yap1 transcripts are detected in
neural tissue, mesenchyme and Rathke’s pouch epithelium between 10.5dpc and 13.5dpc (A–C, arrowheads indicating RP expression). Note the dorsal expression
bias at 12.5dpc and 13.5dpc and absence of transcripts in the rostral tip (arrows in B,C). Transcripts persist in all tissues at 15.5dpc and 17.5dpc especially in the
periluminal region (black arrowhead in D) and epithelium surrounding the third ventricle (white arrowheads in D,E). (F–Y) Expression of Tead1, Tead2, Tead3, and
Tead4 encoding TEAD transcription factors. Tead1 and Tead3 transcripts are detectable in all tissues at low levels (F–J,P–T), higher in RP (arrowheads in F,H,P–R).
Tead2 is highly expressed in all tissues at 10.5dpc (K), and from 12.5dpc becomes restricted to the ventral diencephalon in neural tissue (L,M) and to the epithelium
surrounding the third ventricle (white arrowheads in N,O). Tead2 is strongly expressed in the periluminal epithelium of the anterior pituitary primordium (black
arrowheads L–O) but excluded from the rostral tip (arrows L,M). Tead4 transcripts are barely detectable (U–Y). Abbreviations: rp, Rathke’s pouch; vd, ventral
diencephalon; m, mesenchyme; inf, infundibulum; sph, sphenoid; rt, rostral tip; pl, posterior lobe; al, anterior lobe; il, intermediate lobe; hy, hypothalamus; 3v, third
ventricle. Sagittal sections between 10.5dpc and 13.5dpc and frontal between 15.5dpc and 17.5dpc. Axes in (A) applicable to (A–C,F–H,K–M,P–R,U–W: d, dorsal;
v, ventral; r, rostral; c, caudal). Axes in (D) applicable to (D,E,I,J,N,O,S,T,X,Y: d, dorsal; v, ventral; ri, right; le, left). Scale bars 200 µm.
positivity, with some GFP+ cells showing stronger staining for
pYAP1 protein (yellow arrowheads in Figure 6G) and lower
levels in others (green arrowheads in Figure 6G).
DISCUSSION
Coordinating proliferation, differentiation and cell death is
critical for normal development of tissues and for maintaining
the balance of cells during long-term homeostasis. The Hippo
kinase cascade has been shown to mediate these processes
through the inhibition of proliferation and promotion of
differentiation and cell death. In this manuscript we reveal
that the Hippo signaling cascade is active during all stages of
embryonic pituitary development assessed and continues to act
in the postnatal organ.
The genes Mst1 and Mst2 encoding the core Hippo kinases,
are both expressed throughout the developing pituitary and Lats1
is expressed at high levels during development. Since we barely
detected expression of Lats2, we hypothesize the main kinase
upstream of YAP1/TAZ in the gland is likely to be Lats1. From the
four Tead genes that encode the pathway transcription factors,
Tead2 is the highest expressed making it likely to act as the main
regulator of downstream target gene transcription. Interestingly,
expression of Yap1 is very similar to Tead2, which are both
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FIGURE 5 | Expression of YAP1 and TAZ proteins during embryonic development. Immunofluorescence using specific antibodies against total TAZ protein,
total YAP1 protein and phosphorylated YAP1 (S127) in red. Nuclei are counterstained with DAPI (blue). (A–J) Localization of effectors TAZ (A–E) and YAP1 (F–J) using
antibodies recognizing total protein. Note the nuclear localization in periluminal cells of Rathke’s pouch (yellow arrowheads in B,C,G,H, white arrowheads in D,E,I,J).
No YAP1/TAZ proteins are detected in the rostral tip (arrowheads in B,C,G,H) and there is a reduction in expression in ventral regions (asterisks in B,C,G,H). Note
expression in structures resembling capillaries from 15.5dpc (arrows in D,E,J). (K–O) Immunofluorescence to detect the phosphorylated form of YAP1 at S127. Protein
detection indicates Hippo kinase cascade activity at all stages, primarily in periluminal RP epithelium (white arrowheads in K,N,O). Note the ventral bias of protein
localization at 12.5dpc and 13.5dpc (yellow arrows in L,M) and complete absence of protein from the rostral tip (white arrowheads in L,M). Boxed inserts show higher
magnifications of the epithelium. Examples of cytoplasmic localization are noted by white arrows and examples of nuclear localization by yellow arrows. Abbreviations:
rp, Rathke’s pouch; vd, ventral diencephalon; m, mesenchyme; oe, oral ectoderm; inf, infundibulum; sph, sphenoid; rt, rostral tip; pl, posterior lobe; al, anterior lobe; il,
intermediate lobe. Sagittal sections between 10.5dpc and 13.5dpc and frontal between 15.5dpc and 17.5dpc. Axes in (A) applicable to (A–C,F–H,K–M: d, dorsal; v,
ventral; r, rostral; c, caudal). Axes in (D) applicable to (D,E,I,J,N,O: d, dorsal; v, ventral; ri, right; le, left). Scale bars 100 µm and 20 µm in boxed inserts.
strongest expressed in the regions rich in stem/progenitor cells.
Expression of both is completely absent from the rostral tip
of the pituitary at 12.5dpc and 13.5dpc, as is expression of
YAP1 and TAZ proteins and of phosphorylated YAP1, despite
positive expression of the kinases Mst1, Mst2, and Lats1 in this
tissue. This suggests that the Hippo cascade is not regulating
the rostral tip, but this region highly expresses Fat4, which
can act as a receptor upstream of the Hippo cascade. Taken
together, we hypothesize that Fat4 is not acting upstream of
Hippo in the rostral tip during development. Expression of
Dchs1 that complements the receptor-ligand interaction is strong
in mesenchyme surrounding Rathke’s pouch, likely acting in
concert with FAT4 at the rostral tip. Both genes are expressed at
low levels in the anterior pituitary and a possible role upstream
of the Hippo cascade cannot be excluded. From this gene family,
Fat3 is also a candidate to encode a protocadherin upstream
of the pathway; its expression in RP resembles that of Yap1
and Tead2, as well as Sox2. These demonstrate a dorsal bias in
expression, at the region of the future intermediate lobe and stem
cell-containing region of the anterior lobe. Expression in the stem
cell-rich periluminal zone persists in the anterior pituitary at later
stages.
We observe strong nuclear localization of YAP1 and TAZ
throughout the stem cell-rich regions of developing Rathke’s
pouch and the postnatal anterior pituitary and reveal that
phosphorylation of YAP1 at S127 occurs, suggesting kinase
activity within the SOX2+ stem cell pool. The S127 residue
is in one of the five LATS phosphorylation consensus motifs
and results in YAP1 regulation by the Hippo pathway through
14-3-3 binding and cytoplasmic retention (Zhao et al., 2007).
Activity of the kinase cascade on the stem/progenitor pool in
the pituitary gland may function to regulate stem cell numbers
or behavior. Additionally, we observe localization of all three
proteins in blood vessels in the gland, which will need to
be taken into account during any interpretation of future
functional data for this pathway in the pituitary. At 12.5dpc
the ventral epithelium of Rathke’s pouch has stronger pYAP1
expression, suggesting that the Hippo cascade may have higher
activity in the ventral, more committed aspect, corroborated
by stronger nuclear expression of total YAP1 and TAZ in the
dorsal epithelium. Several inputs can influence Hippo cascade
activity, such as mechanotransduction, polarity and G-protein-
coupled receptor signaling. More recently, negative regulation of
the cascade by the transcription factor SOX2 was shown, which
is expressed by many stem cell types, including pituitary stem
cells throughout development and postnatal stages. SOX2 has
been shown to antagonize the function of the Hippo cassette in
two ways: by directly regulating Yap1 transcription (Seo et al.,
2013) as well as by antagonizing NF2 and WWC1, homologs of
Merlin and Kibra respectively, that positively regulate MST1/2
thus resulting in reduced phosphorylation of YAP1/TAZ (Basu-
Roy et al., 2015). This places SOX2 as a likely candidate upstream
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FIGURE 6 | Expression of YAP1 and TAZ proteins in postnatal pituitaries. Immunofluorescence using specific antibodies on frontal sections of dissected
postnatal pituitaries at P21. (A) Immunofluorescence using antibodies against the pituitary stem cell marker SOX2 (red, arrowheads) showing positive staining in the
periluminal epithelium and in small groups of cells throughout the anterior lobe parenchyma. Antibodies against endomucin mark epithelial cells surrounding blood
vessels (green, arrows). (B–D) Immunofluorescence staining against total TAZ protein (B), total YAP1 protein (C) and phosphorylated YAP1 (S127) protein (D) in red.
All three are detected in periluminal cells (white arrowheads) as well as structures resembling blood vessels (white arrows). (E–G) Double immunofluorescence staining
on pituitary sections from Sox2Egfp/+ animals using antibodies against GFP protein in green detecting EGFP and marking SOX2+ cells together with antibodies
against TAZ protein (E), total YAP1 protein (F) and phosphorylated YAP1 (S127) protein (G) in red. Arrows in (E,F) indicate examples of cells with nuclear TAZ or YAP1
protein. Yellow arrowheads in G note examples of GFP+ cells with strong nucleocytoplasmic pYAP1 protein localization and green arrowheads indicate GFP+ cells in
lower pYAP1 levels in the nucleus. Nuclei are counterstained with DAPI (blue). Abbreviations: pl, posterior lobe; al, anterior lobe; il, intermediate lobe. Axes in (A)
applicable to all panels: d, dorsal; v, ventral; ri, right; le, left. Scale bars 100µm in (A–D), 20µm in inserts and 50µm in (E–G).
of the Hippo cascade in the pituitary gland, and its potential role
to maintain the stem/progenitor cell state through this pathway
can be addressed in future.
Our results suggest there is appropriate expression of Hippo
pathway components to support a possible functional role in the
pituitary gland. A previous study reporting over-proliferation of
uncommitted pituitary tissue in the absence of LATS1 kinase
(St John et al., 1999) supports that this pathway may be
acting to regulate homeostasis in the pituitary. It remains to be
determined if the function of LATS1 in the gland is mediated
through YAP1/TAZ. In summary, our results highlight that
Hippo signaling is active in the pituitary gland, both during
development and at postnatal stages and reveal the expression
patterns of its major components. Our studies suggest a possible
role for this pathway in the regulation of the uncommitted
stem/progenitor cell pool, with its function remaining to be
elucidated.
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